Science
Science: Intrinsic disorder and transcriptional addiction in cancer
An enormous opportunity for the next wave of transformational cancer therapeutics
>300
transcription factors have a known causal role in driving human cancers
Zero
drugs approved that target the intrinsically-disordered regions of disease-causing proteins
Transcription Factors
The Master Regulators of Cancer
Transcription factors are central players in cancer biology, orchestrating key growth and survival pathways. Hundreds have been identified as primary oncogenic drivers across diverse cancer types. A hallmark feature of many oncogenic transcription factors is their high degree of intrinsic disorder. This makes them notoriously difficult to target with conventional drug discovery.
With the right approach, what was once considered impossible becomes possible.
Nuage’s pioneering approach enables development of innovative therapies with the potential to target cancer growth dependencies according to a whole new paradigm.
The implications are immense. As transcription factors are often highly specific to certain cancers and play a pivotal role in cancer signalling, targeting them sets new standards for personalised and targeted treatments.
The implications are immense. As transcription factors are often highly specific to certain cancers and play a pivotal role in cancer signalling, targeting them sets new standards for personalised and targeted treatments.
1
Specific binding
Our small molecules are designed to interact selectively with the target in its druggable conformation
2
Locked interaction
Covalent reaction provides sustained binding to the disordered region, inhibiting key transcription factor functions
3
Inhibiting Transcription
By inhibiting transcription factors we can downregulate the expression of oncogenic genes, driving down cancer growth.
Cancer is just the start
Beyond oncology, structural disorder plays a key role in a range of other key therapeutic areas, including neurodegenerative diseases, autoimmune disorders and many more.